The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements
Open accessAbstract
Purpose: Cardiac involvement predicts poor prognosis in light chain (AL) amyloidosis, and the current prognostic classification is based on cardiac biomarkers troponin-T (cTnT) and N-terminal pro–B-type natriuretic peptide (NT-ProBNP). However, long-term outcome is dependent on the underlying plasma cell clone, and incorporation of clonal characteristics may allow for better risk stratification. Patients and Methods: We developed a prognostic model based on 810 patients with newly diagnosed AL amyloidosis, which was further examined in two other datasets: 303 patients undergoing stem-cell transplantation, and 103 patients enrolled onto different clinical trials. Results: We examined the prognostic value of plasma cell–related characteristics (ie, difference between involved and uninvolved light chain [FLC-diff], marrow plasma cell percentage, circulating plasma cells, plasma cell labeling index, and β 2 microglobulin). In a multivariate model that included these characteristics as well as cTnT and NT-ProBNP, only FLC-diff, cTnT, and NT-ProBNP were independently prognostic for overall survival (OS). Patients were assigned a score of 1 for each of FLC-diff ≥ 18 mg/dL, cTnT ≥ 0.025 ng/mL, and NT-ProBNP ≥ 1,800 pg/mL, creating stages I to IV with scores of 0 to 3 points, respectively. The proportions of patients with stages I, II, III and IV disease were 189 (25%), 206 (27%), 186 (25%) and 177 (23%), and their median OS from diagnosis was 94.1, 40.3, 14, and 5.8 months, respectively (P < .001). This classification system was validated in the other datasets. Conclusion: Incorporation of serum FLC-diff into the current staging system improves risk stratification for patients with AL amyloidosis and will help develop risk-adapted therapies for AL amyloidosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
Self-citationPrimary systemic amyloidosis: clinical and laboratory features in 474 cases.
Kyle, R. A., & Ma, G. (1995) · PubMed · Cited by 1,255
Self-citationDispenzieri, A., Gertz, M. A., Kyle, R. A., Lacy, M. Q., Burritt, M. F., Therneau, T. M., Greipp, P. R., Witzig, T. E., Lust, J. A., Rajkumar, S. V., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.029 · Cited by 985
Self-citationBettencourt, P., Azevedo, A., Pimenta, J., Friões, F., Ferreira, S., & Ferreira, A. (2004) · Circulation · doi:10.1161/01.cir.0000144310.04433.be · Cited by 729
Amyloidosis: Pathogenesis and New Therapeutic Options
Merlini, G., Seldin, D. C., & Gertz, M. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2271 · Cited by 509
Self-citationDispenzieri, A. A., Gertz, M. A., Kyle, R. A., Lacy, M. Q., Burritt, M. F., Therneau, T. M., McConnell, J. P., Litzow, M. R., Gastineau, D. A., Tefferi, A., et al. (2004) · Blood · doi:10.1182/blood-2004-01-0390 · Cited by 320
Self-citationSurvival in patients with primary systemic amyloidosis and raised serum cardiac troponins
Dispenzieri, A., Kyle, R. A., Gertz, M. A., Therneau, T. M., Miller, W. L., Chandrasekaran, K., McConnell, J. P., Burritt, M. F., & Jaffe, A. S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13396-x · Cited by 317
Self-citationBortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis
Kastritis, E., Wechalekar, A. D., Dimopoulos, M. A., Merlini, G., Hawkins, P. N., Perfetti, V., Gillmore, J. D., & Palladini, G. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8220 · Cited by 298
Dispenzieri, A., Lacy, M. Q., Zeldenrust, S. R., Hayman, S. R., Kumar, S. K., Geyer, S. M., Lust, J. A., Allred, J. B., Witzig, T. E., Rajkumar, S. V., et al. (2007) · Blood · doi:10.1182/blood-2006-07-032987 · Cited by 273
Self-citationDiagnostic Performance of Quantitative κ and λ Free Light Chain Assays in Clinical Practice
Katzmann, J. A., Abraham, R. S., Dispenzieri, A., Lust, J. A., & Kyle, R. A. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.046870 · Cited by 265
Self-citation
Cited by
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
2023 ESC guidelines for the management of cardiomyopathies
Arbelo, E., Protonotarios, A., Gimeno, J. R., Arbustini, E., Barriales-Villa, R., Basso, C., Bezzina, C. R., Biagini, E., Blom, N. A., de Boer, R. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad194 · Cited by 2,844
Garcia-Pavia, P., Rapezzi, C., Adler, Y., Arad, M., Basso, C., Brucato, A., Burazor, I., Caforio, A. L. P., Damy, T., Eriksson, U., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab072 · Cited by 1,231
Grogan, M., Scott, C. G., Kyle, R. A., Zeldenrust, S. R., Gertz, M. A., Lin, G., Klarich, K. W., Miller, W. L., Maleszewski, J. J., & Dispenzieri, A. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.06.033 · Cited by 763
Self-citationAL (Light-Chain) Cardiac Amyloidosis
Falk, R. H., Alexander, K. M., Liao, R., & Dorbala, S. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.06.053 · Cited by 649
Kittleson, M. M., Ruberg, F. L., Ambardekar, A. V., Brannagan, T. H., Cheng, R. K., Clarke, J. O., Dember, L. M., Frantz, J. G., Hershberger, R. E., Maurer, M. S., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.11.022 · Cited by 640
Maurer, M. S., Bokhari, S., Damy, T., Dorbala, S., Drachman, B. M., Fontana, M., Grogan, M., Kristen, A. V., Lousada, I., Nativi-Nicolau, J., et al. (2019) · Circulation: Heart Failure · doi:10.1161/circheartfailure.119.006075 · Cited by 568
Systemic immunoglobulin light chain amyloidosis
Merlini, G., Dispenzieri, A., Sanchorawala, V., Schönland, S. O., Palladini, G., Hawkins, P. N., & Gertz, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0034-3 · Cited by 552
Self-citationLyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeac106 · Cited by 507
Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis
Maurer, M. S., Elliott, P., Comenzo, R., Semigran, M., & Rapezzi, C. (2017) · Circulation · doi:10.1161/circulationaha.116.024438 · Cited by 492
Dorbala, S., Ando, Y., Bokhari, S., Dispenzieri, A., Falk, R. H., Ferrari, V. A., Fontana, M., Gheysens, O., Gillmore, J. D., Glaudemans, A. W. J. M., et al. (2019) · Journal of Nuclear Cardiology · doi:10.1007/s12350-019-01760-6 · Cited by 484
Self-citationGlobal burden of hematologic malignancies and evolution patterns over the past 30 years
Zhang, N., Wu, J., Wang, Q., Liang, Y., Li, X., Chen, G., Ma, L., Liu, X., & Zhou, F. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00853-3 · Cited by 432
Castano, A., Haq, M., Narotsky, D. L., Goldsmith, J., Weinberg, R. L., Morgenstern, R., Pozniakoff, T., Ruberg, F. L., Miller, E. J., Berk, J. L., et al. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.2839 · Cited by 424
Self-citationT1 mapping and survival in systemic light-chain amyloidosis
Banypersad, S. M., Fontana, M., Maestrini, V., Sado, D. M., Captur, G., Petrie, A., Piechnik, S. K., Whelan, C. J., Herrey, A. S., Gillmore, J. D., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu444 · Cited by 393
Comenzo, R. L., Reece, D., Palladini, G., Seldin, D., Sanchorawala, V, Landau, H., Falk, R., Wells, K., Solomon, A., Wechalekar, A., et al. (2012) · Leukemia · doi:10.1038/leu.2012.100 · Cited by 390
Self-citationSystemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review
Gertz, M. A., & Dispenzieri, A. (2020) · JAMA · doi:10.1001/jama.2020.5493 · Cited by 366
Self-citationGarcia‐Pavia, P., Rapezzi, C., Adler, Y., Arad, M., Basso, C., Brucato, A., Burazor, I., Caforio, A. L. P., Damy, T., Eriksson, U., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2140 · Cited by 349
Seferović, P. M., Polovina, M., Bauersachs, J., Arad, M., Ben Gal, T., Lund, L. H., Felix, S. B., Arbustini, E., Caforio, A. L. P., Farmakis, D., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1461 · Cited by 346
Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment
Siddiqi, O. K., & Ruberg, F. L. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.07.004 · Cited by 333
Restrictive Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy
Muchtar, E., Blauwet, L. A., & Gertz, M. A. (2017) · Circulation Research · doi:10.1161/circresaha.117.310982 · Cited by 327
Self-citationSystemic amyloidosis from A (AA) to T (ATTR): a review
Muchtar, E., Dispenzieri, A., Magen, H., Grogan, M., Mauermann, M., McPhail, E. D., Kurtin, P. J., Leung, N., Buadi, F. K., Dingli, D., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13169 · Cited by 327
Self-citationHow I treat monoclonal gammopathy of renal significance (MGRS)
Fermand, J.-P., Bridoux, F., Kyle, R. A., Kastritis, E., Weiss, B. M., Cook, M. A., Drayson, M. T., Dispenzieri, A., & Leung, N. (2013) · Blood · doi:10.1182/blood-2013-05-495929 · Cited by 326
Self-citationDorbala, S., Ando, Y., Bokhari, S., Dispenzieri, A., Falk, R. H., Ferrari, V. A., Fontana, M., Gheysens, O., Gillmore, J. D., Glaudemans, A. W. J. M., et al. (2021) · Circulation: Cardiovascular Imaging · doi:10.1161/hci.0000000000000029 · Cited by 275
Self-citation
Metadata
- Authors
- Kumar, S., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Colby, C., Laumann, K., Zeldenrust, S. R., Leung, N., Dingli, D., Greipp, P. R., Lust, J. A., Russell, S. J., Kyle, R. A., Rajkumar, S. V., & Gertz, M. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-03-20
- Volume
- 30
- Issue
- 9
- Pages
- 989-995
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2171033052
- Cited by
- 1,137
- References
- 21
- FWCI
- 13.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.